Streetbeat News

Earnings

RMNI

Rimini Street (NASDAQ:RMNI) reported Q3 2023 earnings of $0.13 per share, beating the analyst consensus estimate of $0.10 by 30%. This is a 44.44% increase from the same period last year. The company also reported quarterly sales of $107.45 million, beating the analyst consensus estimate of $106.32 million by 1.07%. This is a 5.42% increase from the same period last year.

Portfolio Pulse from totan@benzinga.com

November 01, 2023 | 9:04 pm

NTR

Nutrien (NYSE:NTR) reported Q3 adjusted earnings of $0.35 per share, missing the analyst consensus estimate of $0.65 by 46.15%. This is a 86.06% decrease from the same period last year. The company also reported quarterly sales of $5.63 billion, missing the analyst consensus estimate of $5.70 billion by 1.18%. This is a 31.23% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 9:04 pm

BMRN

Biomarin Pharmaceutical reported Q3 earnings of $0.46 per share, beating the analyst consensus estimate of $0.22 by 109.09%. This is a significant increase from losses of $(0.04) per share from the same period last year. However, the company's quarterly sales of $581.33 million missed the analyst consensus estimate of $608.68 million by 4.49%.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 9:04 pm

CFLT

Confluent has projected its Q4 2023 adjusted EPS to be $0.05, which is in line with estimates. However, the company's revenue forecast of $204M-$205M falls short of the estimated $212.6M.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 9:03 pm

VMD

Viemed Healthcare (NASDAQ:VMD) reported Q3 2023 earnings of $0.07 per share, missing the analyst consensus estimate of $0.08 by 12.5%. The company also reported quarterly sales of $49.40 million, missing the analyst consensus estimate of $49.50 million by 0.20%. However, both earnings and sales have increased compared to the same period last year.

Portfolio Pulse from saritha@benzinga.com

November 01, 2023 | 9:03 pm

RVLV

Revolve Gr (NYSE:RVLV) reported Q3 earnings of $0.04 per share, missing the analyst consensus estimate of $0.10 by 60%. This is a 75% decrease from the same period last year. However, the company reported quarterly sales of $257.60 million, beating the analyst consensus estimate of $254.99 million by 1.02%.

Portfolio Pulse from bharat@benzinga.com

November 01, 2023 | 9:03 pm

PRCT

PROCEPT BioRobotics (NASDAQ:PRCT) reported Q3 losses of $(0.51) per share, beating the analyst consensus estimate of $(0.53) by 3.77%. The company's quarterly sales were $35.10 million, surpassing the analyst consensus estimate of $33.09 million by 6.08%. This represents a 72.50% increase over sales of $20.35 million in the same period last year.

Portfolio Pulse from mahesh@benzinga.com

November 01, 2023 | 9:02 pm

SRPT

Sarepta Therapeutics reported Q3 earnings of $0.37 per share, beating the analyst consensus estimate of $(1.33) by 127.82%. This is a 146.25% increase over losses of $(0.80) per share from the same period last year. The company also reported quarterly sales of $331.82 million, beating the analyst consensus estimate of $285.83 million by 16.09%. This is a 44.10% increase over sales of $230.27 million the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 9:02 pm

ERII

Energy Recovery (NASDAQ:ERII) reported Q3 earnings of $0.20 per share, beating the analyst consensus estimate of $0.04 by 400%. This is a 66.67% increase from the same period last year. The company also reported quarterly sales of $37.04 million, beating the analyst consensus estimate of $31.29 million by 18.36%. This is a 21.58% increase from the same period last year.

Portfolio Pulse from bharat@benzinga.com

November 01, 2023 | 9:02 pm

KW

Kennedy-Wilson Holdings (NYSE:KW) reported Q3 2023 earnings with an adjusted EPS of $(0.34), missing the analyst consensus estimate of $0.08 by 525%. This is a 383.33% decrease from the same period last year. However, the company's quarterly sales of $141.30 million beat the analyst consensus estimate of $130.88 million by 7.96%, a 1.22% increase from the same period last year.

Portfolio Pulse from totan@benzinga.com

November 01, 2023 | 9:02 pm